Kosei Ishimaru, Masataka Ikeda, Hiroko Deguchi Miyamoto, Shun Furusawa, Ko Abe, Masatsugu Watanabe, Takuya Kanamura, Satoshi Fujita, Ryohei Nishimura, Takayuki Toyohara, Shouji Matsushima, Tomoko Koumura, Ken-Ichi Yamada, Hirotaka Imai, Hiroyuki Tsutsui, Tomomi Ide
BACKGROUND: Ferroptosis, an iron-dependent form of regulated cell death, is a major cell death mode in myocardial ischemia reperfusion (I/R) injury, along with mitochondrial permeability transition-driven necrosis, which is inhibited by cyclosporine A (CsA). However, therapeutics targeting ferroptosis during myocardial I/R injury have not yet been developed. Hence, we aimed to investigate the therapeutic efficacy of deferasirox, an iron chelator, against hypoxia/reoxygenation-induced ferroptosis in cultured cardiomyocytes and myocardial I/R injury...
January 2, 2024: Journal of the American Heart Association